# Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

> **NCT03356860** · PHASE1,PHASE2 · COMPLETED · sponsor: **Grand Hôpital de Charleroi** · enrollment: 57 (actual)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer
- Luminal B

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03356860
- **Lead sponsor:** Grand Hôpital de Charleroi
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-13
- **Primary completion:** 2022-11-21
- **Final completion:** 2023-12-31
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03356860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03356860, "Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03356860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*